抄録
We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.
本文言語 | English |
---|---|
ページ(範囲) | 1058-1060 |
ページ数 | 3 |
ジャーナル | Pediatric Blood and Cancer |
巻 | 62 |
号 | 6 |
DOI | |
出版ステータス | Published - 2015 6月 1 |
外部発表 | はい |
ASJC Scopus subject areas
- 小児科学、周産期医学および子どもの健康
- 血液学
- 腫瘍学